Skip to main content

Table 1 Signalment of primary dogs enrolled as veterinary patients in studies conducted in Europe to evaluate the efficacy of Simparica Trio™ against natural flea and tick infestations

From: Efficacy of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against natural flea and tick infestations on dogs presented as veterinary patients in Europe

Signalment

Flea study

Tick study

Simparica Trio™ (n = 180)

Afoxolaner + Milbemycin oxime (n = 98)

Simparica Trio™ (n = 126)

Afoxolaner + Milbemycin oxime (n = 64)

Purebred

64

41

71

41

Non-purebred

116

57

55

23

Age, mean (years)

4.8

4.3

4.7

4.7

Age, range (years)

0.2–15.0

0.2–16.0

0.2–14.0

0.3–14.0

Body weight, mean (kg)

14.2

15.5

19.4

21.1

Body weight, range (kg)

2.1–48.8

2.7–50.9

2.1–65.1

2.7–54.3

Male

98

52

75

38

Female

82

46

51

26

Lives mostly indoors

20

7

11

4

Lives mostly outdoors

116

63

73

45

Lives indoors and outdoors

44

28

42

15